Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab

Nivolumab has shown good prognosis in renal cell carcinoma (RCC) patients previously treated with targeted therapy. We aimed to study irAE (immune-related adverse event) due to nivolumab and numbers of previous treatment lines in RCC patients. Between October 2016 and November 2019, 114 patients wer...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Medicine (Baltimore)
Main Authors: Mizutani, Kosuke, Ito, Toshiki, Takahara, Kiyoshi, Ando, Ryosuke, Ishihara, Takuma, Yasui, Takahiro, Shiroki, Ryoichi, Miyake, Hideaki, Koie, Takuya
Format: Artigo
Jezik:Inglês
Izdano: Lippincott Williams & Wilkins 2021
Teme:
7300
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8021322/
https://ncbi.nlm.nih.gov/pubmed/33787647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000025402
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki